Molecular and Cellular Biology, July 2001, p. 4713-4724, Vol. 21, No. 14
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.14.4713-4724.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Department of Pathology and Center for Neurobiology and Behavior, College of Physicians and Surgeons, Columbia University, New York, New York 10032,1 and Cephalon Incorporated, West Chester, Pennsylvania 193802
Received 9 April 2001/Accepted 16 April 2001
| |
ABSTRACT |
|---|
|
|
|---|
Neuronal apoptotic death induced by nerve growth factor (NGF) deprivation is reported to be in part mediated through a pathway that includes Rac1 and Cdc42, mitogen-activated protein kinase kinases 4 and 7 (MKK4 and -7), c-Jun N-terminal kinases (JNKs), and c-Jun. However, additional components of the pathway remain to be defined. We show here that members of the mixed-lineage kinase (MLK) family (including MLK1, MLK2, MLK3, and dual leucine zipper kinase [DLK]) are expressed in neuronal cells and are likely to act between Rac1/Cdc42 and MKK4 and -7 in death signaling. Overexpression of MLKs effectively induces apoptotic death of cultured neuronal PC12 cells and sympathetic neurons, while expression of dominant-negative forms of MLKs suppresses death evoked by NGF deprivation or expression of activated forms of Rac1 and Cdc42. CEP-1347 (KT7515), which blocks neuronal death caused by NGF deprivation and a variety of additional apoptotic stimuli and which selectively inhibits the activities of MLKs, effectively protects neuronal PC12 cells from death induced by overexpression of MLK family members. In addition, NGF deprivation or UV irradiation leads to an increase in both level and phosphorylation of endogenous DLK. These observations support a role for MLKs in the neuronal death mechanism. With respect to ordering the death pathway, dominant-negative forms of MKK4 and -7 and c-Jun are protective against death induced by MLK overexpression, placing MLKs upstream of these kinases. Additional findings place the MLKs upstream of mitochondrial cytochrome c release and caspase activation.
| |
INTRODUCTION |
|---|
|
|
|---|
There has been much progress in defining the general mechanisms by which neurons and other cell types die in response to apoptotic stimuli. However, the components and order of the transducing pathways that mediate death are still not completely understood. One apoptotic pathway that appears to be particularly important in neurons includes the c-Jun N-terminal kinases (JNKs; also known as the stress-activated protein kinases) (14, 15, 22, 32, 42, 69; reviewed in reference 23). JNKs are phosphorylated and activated in response to a variety of apoptotic stimuli, including tumor necrosis factor, DNA damage, heat shock, ischemia-reperfusion, oxidative stress, hyperosmolarity, axonal injury, and loss of trophic support (20, 31, 38, 42, 55, 68, 69). Various types of evidence indicate that JNK activation plays a required role in many such paradigms of neuronal cell death. A well-defined downstream target of activated JNKs in neuronal cells that also plays an obligatory part in death is c-Jun (14, 15, 22). Neuronal c-Jun levels are elevated in response to trophic factor withdrawal, and dominant-negative forms of this transcription factor are protective against death evoked by loss of trophic support as well as by selective activation of JNKs (14, 22).
Several upstream members of the death-related JNK/c-Jun pathway have also been defined. The most distal of these are the Rho small GTPase family members Rac1 and Cdc42. Overexpression of constitutively active forms of Rac1 and Cdc42 (Rac1 V12 [mutated at position 12 to V] and Cdc42 V12) leads to activation of the JNK pathway and to death of Jurkat T lymphocytes, PC12 cells, and sympathetic neurons; conversely, overexpression of dominant-negative mutants of Cdc42 and Rac1 (Cdc42 N17 and Rac1 N17) in sympathetic neurons prevents elevation of c-Jun and death evoked by nerve growth factor (NGF) withdrawal (2, 7). Overexpression of Rac1 N17 reverses the induction of death by Cdc42 V12, whereas Cdc42 N17 has no effect on Rac1 V12-induced death, suggesting that Cdc42 lies upstream of Rac1 (2). Similar approaches have indicated that mitogen-activated protein kinase kinases 4 and 7 (MKK4 and MKK7) lie downstream of Cdc42 and Rac1 and directly upstream of the JNKs (17, 27, 45, 65, 69, 70). Finally, recent studies using constitutively active and dominant-negative constructs have implicated apoptosis signal-regulating kinase 1 (ASK1) as an additional participant in the pathway that lies between Cdc42 and the downstream MKKs and JNKs (32).
The mixed-lineage kinases (MLKs) represent an additional family that has the potential to be involved in the JNK activation pathway. MLKs have been shown to function as MKK kinases and lead to activation of JNKs via activation of MKKs (4, 9, 25, 46, 56, 63, 65). Members of the family include MLK1, MLK2 (also called MST), MLK3 (also called SPRK or PTK1), dual leucine zipper kinase (DLK; also called MUK or ZPK), and leucine zipper-bearing kinase (LZK) (12, 28, 30, 48, 57). In addition to a kinase domain, MLK family members possess one or two leucine zipper domains, and MLK1, -2, and -3, but not DLK, also have an SH3 domain and a potential Cdc42-Rac interactive binding (CRIB) motif (5, 12, 30). Constitutively active mutants of Rac1 and Cdc42 have been found to bind to and to modulate the activities of MLK2 and -3, and coexpression of MLK3 and activated Cdc42 leads to enhanced MLK3 activation, which is reported to require the presence of the MLK3 CRIB motif (4, 5, 48, 62).
Because of the widespread role of JNK activation in neuronal death signaling, we have carried out further studies to define the identities and relative order of the components of this pathway. Here, we show in particular that MLKs are mediators of JNK activation in neuronal cells.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials.
Cell growth media RPMI 1640 and Dulbecco's
minimal essential medium, Taq Platinum DNA polymerase, and
Lipofectamine Plus were purchased from Life Technologies, Inc.
(Frederick, Md.). Human recombinant NGF was kindly provided by
Genentech (South San Francisco, Calif.).
(
)cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8[4-(3-hydroxy-1-methyl)piperidinyl]-4H-benzopyran-4-one (L86-8275; flavopiridol) was a generous gift from Peter J. Worland (National Cancer Institute). Boc-aspartyl-(ome)-fluoromethyl ketone (BAF), Ac-DEVD-pNA, and zVAD-fluoromethylketone (zVAD-fmk) were purchased from Enzyme Systems Products (Dublin, Calif.). Hoechst dye
33342, mouse NGF, and anti-mouse NGF antiserum were obtained from Sigma
(St. Louis, Mo.). Phospho-AKT (Ser473) antiserum was purchased from New
England Biolabs (Beverly, Mass.). DLK antiserum was purchased from
StressGen (Victoria, British Columbia, Canada). MLK3 antiserum was
purchased from Santa Cruz (Santa Cruz, Calif.). CEP-1347 was
solubilized in dimethyl sulfoxide at a concentration of 4 mM and stored
at
20°C in amber glass vials. Further dilutions were made from this
stock directly into media.
RT-PCR analysis. Expression of MLK1, MLK2, MLK3, DLK, and LZK was determined by reverse transcription (RT)-PCR analysis. Total RNA was purified using RNAzolB (TelTest Inc., Friendswood, Tex.), and Superscript II reverse transcriptase (Life Technologies) was used to synthesize cDNA. PCR assays were performed as previously described (3). The following primers were used: MLK1, 5'-AACTACGTGACCCCGCGCA-3' and 5'-CCGCAAAATCAATTTCTAAC-3'; MLK2, 5'-TGGAGCTGGAGAGCTTCAAGAAG-3' and 5'CAT GTCCATGTCCAGCAGTGTGG-3'; MLK3, 5'-GTCATGGAATGGCAGTGG-3' and 5'-CACGGTCACCCTTCCTCA-3'; DLK, 5'-GAGGTAGACAGTGAAGTAGAGC-3' and 5'-CCAATTCAGTGCTGTCACAGTC-3'; LZK, 5'-CACCAGCACATAATCCTCTCTTG-3' and 5'-CACTGGTATTTCCCTCTTCTCC-3'; and cyclophilin, 5'-ATGGTCAACCCCACCGTGTT-3' and 5'-CTGGTGAAGTCACCACCCT-3'. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) primers were purchased from Clontech (Palo Alto, Calif.). The identity of all PCR products was confirmed by sequencing. All RT-PCR assays were performed at least twice, except that for LZK in superior cervical ganglion (SCG) cells, which was done once. Representative results are shown.
cDNA constructs in mammalian expression vectors.
The cDNAs
for MKK4b (MKK4) and MKK7
1 (MKK7) were PCR amplified from human
placenta and brain, respectively, sequence verified, and inserted into
pcDNA3.1 (Invitrogen, San Diego, Calif.). The cDNAs encoding the K113A
mutant of MKK4 (26) and the K149A mutant of MKK7 were
generated by PCR-mediated site-directed mutagenesis. A truncated cDNA
of mouse MEKK1 (encoding amino acids 817 to 1493 of full-length MEKK1)
was kindly provided by J. Silvio Gutkind (National Institutes of Health
[NIH], Bethesda, Md.) and subcloned into the pcDNA3 vector
(Invitrogen). The following constructs were generously provided as
follows. Both dominant-negative and constitutively active forms of Rac1
and Cdc42 were from Alan Hall (University College London, London,
United Kingdom), and both the dominant-negative form and a
constitutively active form of human ASK1 (or MEKK5) were from Hidenori
Ichijo (Tokyo Medical and Dental University, Tokyo, Japan). Wild-type
c-Jun and dominant-negative c-Jun (TAM67 c-Jun) were from Michael J. Birrer (NIH, Rockville, Md.), and different constructs of AKT,
including wild-type, active, dominant-negative, and myristylated forms,
were kindly provided by Thomas Franke (Columbia University, New York,
NY.). Mouse MKK7 and DLK were from Larry Holzman (University of
Michigan Medical School, Ann Arbor, Mich.). Human MLK3 was kindly
provided by Richard Spritz (University of Wisconsin, Madison, Wis.),
and MLK1 and MLK2 were cloned from human brain cDNA. MLK2, MLK3, and
DLK were subcloned into pcDNA3.1, whereas MLK1 was subcloned into
pcDNA4/HisMax (Invitrogen). cDNA encoding the kinase-inactive mutant
forms of MLK1 (K171A), MLK2 (K125A), MLK3 (K144R), and DLK (K155A) were generated by PCR-mediated site-directed mutagenesis. Sequences encoding
the constitutively active form of human ASK1 (
N ASK1), Rac1 V12,
Cdc42 V12, and both the wild-type and the kinase-inactive mutant forms
of MLK1, MLK2, MLK3, and DLK were subcloned into pCMV.EGFP vector (Clontech).
Cell culture. PC12 cells were cultured as described previously in collagen-coated dishes with RPMI 1640 medium supplemented with 10% heat-inactivated horse serum and 5% fetal bovine serum (21). Neuronal differentiation was induced by NGF (100 ng of human recombinant protein per ml) in RPMI 1640 medium supplemented with 1% heat-inactivated donor horse serum.
Primary cultures of rat sympathetic neurons were generated from dissociated SCG of postnatal-day-1 Sprague-Dawley rats as described previously (39). The cells were plated onto collagen-coated 24-well dishes at a density of around one ganglion per well and maintained in RPMI 1640 medium supplemented with 10% heat-inactivated donor serum and 60 ng of mouse NGF per ml. A mixture of uridine and 5-fluorodeoxyuridine (10 µM each) was added on the following day to eliminate nonneuronal cells.Transfections. DNA used for transfection was prepared with a plasmid maxi kit (Qiagen, Valencia, Calif.). Three independent plasmid preparations were obtained, and the one with the highest transfection efficiency was used in experiments. PC12 cells were transfected with 1.0 µg of plasmid in six-well dishes and 0.5 µg of plasmid in 24-well dishes 4 to 7 days after NGF treatment or overnight after plating for naive cells using Lipofectamine Plus (Life Technologies). Six to nine hours later, medium with Lipofectamine Plus was replaced with fresh medium with NGF or with serum for neuronally differentiated or naive PC12 cells, respectively. Rat sympathetic neurons were transfected with the Helios Gene Gun system (Bio-Rad, Hercules, Calif.).
Trophic factor deprivation. For trophic factor deprivation of PC12 cells, on day 3 after transfection, cultures were washed three times with RPMI 1640 medium, scraped (for neuronally differentiated PC12 cells) or mechanically dislodged (for naive PC12 cells) from their dishes, pelleted at low speed, and washed with serum-free medium. The spin-and-wash procedure was repeated five more times, and the cells were replated into collagen-coated 15-mm wells at approximately 2 × 105 cells per well. Trophic-factor-deprived cultures were maintained in RPMI 1640 medium, and the control nondeprived cells were supported with NGF or serum for NGF-differentiated cells or naive cells, respectively. NGF deprivation of rat sympathetic neurons was performed by washing with NGF-free medium twice and adding anti-NGF antibody (1:150 dilution), as previously described (53). Control cells were washed with serum-free medium and maintained in medium supplied with NGF and 1% horse donor serum.
Assessment of cell survival. (i) Strip counting. From a defined time point (consistent throughout the course of the experiment), the number of healthy, nonapoptotic enhanced green fluorescent protein (EGFP)-positive cells in the same field (consisting of a strip across the diameter of each well) was assessed. The percentage of surviving cells was calculated relative to the numbers present in control wells. The numbers of transfected cells counted in control cultures were at least 400.
(ii) Apoptotic nuclei. Nuclei were visualized by staining cells either alive, or after fixation. To stain living cells, Hoechst dye 33342 at 1 mg/ml was added to the medium to a final concentration of 1 µg/ml. Five minutes later, the medium was replaced with fresh medium without the dye. Otherwise, cells were fixed in 4% formaldehyde for 10 min and then incubated with Hoechst dye 33342 at 1 µg/ml in phosphate-buffered saline (PBS) for 5 min at room temperature without formaldehyde. The medium containing Hoechst dye was then replaced with PBS. Cells possessing condensed nuclei or fragmented chromatin were scored as apoptotic. The number of cells assessed per culture typically ranged from 100 to 200. All experiments were performed at least in triplicate, and results are reported as the means ± standard errors of the means (SEM).
Western immunoblotting.
PC12 cells were harvested in lysis
buffer (10 mM Tris [pH 7.4], 1.0% Triton X-100, 0.5% Nonidet P-40,
150 mM NaCl, 20 mM sodium fluoride, 0.2 mM sodium orthovanadate, 1.0 mM
EDTA, 1.0 mM EGTA, 0.2 mM phenylmethylsulfonyl fluoride). For samples
subjected to phosphatase treatment, sodium orthovanadate was omitted.
Cells were incubated in lysis buffer for 10 min and then scraped from the dishes and passed 10 times through a 26-gauge needle. The lysates
were then centrifuged at 16,000 × g for 20 min, and
the pellets were discarded. Phosphatase treatment was performed by incubating the cell extracts with 400 U of
phosphatase for 2 h
at 30°C according to the manufacturer's instructions (Biolabs). Samples (containing 200 µg of protein) were boiled in 1× sodium dodecyl sulfate sample buffer and separated by sodium dodecyl sulfate-6% polyacrylamide gel electrophoresis prior to blotting on
nitrocellulose membranes (Schleicher & Schuell). The membranes were
incubated in 5% fat-free milk in TBST (25 mM Tris-HCl [pH 7.4], 137 mM NaCl, 5 mM KCl, 0.7 mM CaCl2, 0.1 mM MgCl2,
0.2% [vol/vol] Tween 20) for 2 h and then with the same buffer
containing various dilutions of the primary antibodies (1:200 to
1:250). Before and after incubation with secondary antibody, the
membranes were washed four times for 10 min each time with TBST buffer. The proteins were detected with an appropriate secondary antibody coupled to horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin (Bur73) and visualized by enhanced chemiluminescence according to the instructions of the manufacturer (Amersham Life Science).
Immunofluorescence staining. To detect cytochrome c, cells were fixed with 3% paraformaldehyde for 10 min, washed with PBS, and then permeabilized with 0.5% Triton X-100 and blocked with 10% goat serum for 30 min at room temperature. They were then stained with a specific monoclonal antibody against cytochrome c (clone 6H2.B4; dilution, 1:500; PharMingen, San Diego, Calif.) followed by a rhodamine-conjugated anti-mouse immunoglobulin G antibody (ImmunoPure; 1:500 dilution). To examine nuclear morphology, cells were stained with Hoechst dye (Hoechst 33342; Sigma) at 1 µg/ml.
| |
RESULTS |
|---|
|
|
|---|
MLK family members are expressed in PC12 cells and sympathetic
neurons.
RT-PCR was used to determine expression of members of the
MLK family in PC12 cells and in SCG neurons. As shown in Fig.
1, transcripts for all members of MLK
family were readily detectable in both cell types. Expression in two
different passages of PC12 cells was analyzed. We did not observe
consistent effects of NGF on expression of any of the analyzed genes
(naive versus differentiated cells). Based on approximate equivalency
of GAPDH transcription levels, which served as internal controls, SCG
neurons were found to express severalfold-lower levels of MLK3 and LZK
than PC12 cells. The biological significance, if any, of these
observations is unclear.
|
Expression of MLK family members induces apoptotic death of PC12
cells and sympathetic neurons.
Efforts to establish a permanent
line of PC12 cells expressing MLK3 under the control of the
cytomegalovirus promoter proved to be unsuccessful, thus suggesting
that overexpression of this protein results in cell death. To examine
this issue more fully, sequences encoding MLK3 and the additional
family members MLK1, MLK2, and DLK were cloned into the pCMS.EGFP
vector. A full-length clone for LZK was not available at the time of
this study, and so this enzyme was not included in the present
experiments. The various constructs were transiently transfected into
neuronally differentiated PC12 cells. The GFP signal was detectable
within 1 day and was highest within 2 to 3 days following transfection. Counts of intact GFP-positive cells revealed a rapid decline in numbers
within 4 days for MLK3-transfected cultures but not for empty vector
and kinase-inactive controls (Fig. 2a).
Similar data were obtained with MLK1, MLK2, and DLK. By day 3, cells
transfected with any of the MLK family members had approximately 17%
survival compared with controls (Fig. 2b). Transfection with similar
levels of DNA encoding constitutively active Cdc42 and Rac1 (Cdc42 V12 and Rac1 V12) also evoked death, but in this case survival was approximately 50% by day 3 (Fig. 2b). Death was verified by staining nuclei of transfected cells with Hoechst 33342. Approximately 75% of
nuclei assayed 48 h after transfection with MLKs showed apoptotic
morphology, compared with around 5% in control cultures (Fig. 2c).
Comparable results were achieved with naive, non-NGF-treated cultures
(data not shown). In addition, both naive and neuronally differentiated
PC12 cells transfected with MLKs, but not with kinase-inactive MLKs,
showed additional features of apoptotic responses, including intense
surface blebbing, shrunken cell bodies, and pycnotic nuclei. These
findings demonstrate that overexpression of all MLK family members
tested can efficiently trigger apoptotic death in neuronal cells.
|
|
MLK family members induce death of neuronal PC12 cells by acting
upstream both of MKK4 and -7 and c-Jun and of cytochrome c
release and caspase activation.
DLK has been shown to act upstream
of MKK7, and MLK2 and MLK3 have been shown to act upstream of both MKK4
and MKK7 (9, 46, 56, 63), which, in turn, lie upstream of
JNKs and of c-Jun in the apoptotic pathway activated by NGF deprivation
(14, 15, 22). To assess whether MLK3 and other MLK family
members might also evoke death in neuronal PC12 cells by activating
this pathway, we coexpressed each of them with dominant-negative forms of MKK4, MKK7, and c-Jun. As shown in Fig.
4, the dominant-negative constructs
suppressed death in each case. However, the dominant-negative forms of
MKK4 and MKK7, even when transfected together, only partially suppressed death evoked by overexpression of MLKs and did so to a
significantly lesser degree than the dominant-negative form of c-Jun.
This raises the possibility that MKK4 and MKK7 may not be the only MKKs
that transduce signals from MLKs to c-Jun or that the dominant-negative
MKKs are inefficient with respect to suppression of JNK activation.
|
|
|
Kinase-inactive forms of MLK family members suppress death evoked
by overexpression of MLKs.
Because MLK family members can
homodimerize as well as form complexes with other proteins (41,
65, 67), we tested whether kinase-inactive forms would act as
dominant-negative suppressors of death. A kinase-inactive form of MLK3
(dominant-negative MLK3, MLK3 K144R) was cotransfected into neuronal
PC12 cells along with wild-type MLK1, MLK2, MLK3, or DLK. In each case,
death was strongly suppressed (Fig. 7a).
A kinase-inactive DLK (dominant-negative DLK, DLK K152A) also
effectively blocked death elicited by MLK3 (Fig. 7a). These findings
indicate not only that kinase-inactive MLK forms can act as
dominant-negative forms to suppress death caused by overexpression of
their own wild-type forms but also that they can do so for other
members of the MLK family. Thus, MLK-induced death appears to require
dimerization and/or association with one or more shared binding
partners.
|
Dominant-negative forms of MLKs protect PC12 cells and sympathetic
neurons from death elicited by trophic deprivation.
The above data
indicate that all known MLK family members are present in PC12 cells
and sympathetic neurons, that overexpression of MLKs can stimulate
apoptotic neuronal death, and that such death is suppressed by
dominant-negative MLKs. We therefore determined whether
dominant-negative MLKs would protect against death induced by trophic
factor withdrawal. Neuronal PC12 cells and sympathetic neurons were
transfected with DNA encoding dominant-negative MLK3 or
dominant-negative DLK cloned into the pCMS.EGFP vector and then deprived of NGF. In each case, the dominant-negative forms provided a significant level of protection from death (Fig.
8). The kinase-inactive forms of MLK1 and
MLK2 also provided similar protection for neuronal PC12 cells deprived
of NGF (data not shown).
|
Endogenous DLK is regulated by NGF deprivation and UV
exposure.
We next addressed whether apoptotic stimuli affect
endogenous MLKs. We were unable to reliably detect endogenous MLK1 or
-2 by Western immunoblotting of PC12 cell protein. It is unclear whether this reflects the absence of expression of such proteins (in
contrast to the presence of the corresponding transcripts), the quality
of the available antisera, or low levels of MLK1 and -2 expression. In
contrast, Western immunoblotting revealed endogenous MLK3 and DLK in
naive and neuronally differentiated PC12 cells. Due to its clearer
resolution, we focused on the response of DLK to apoptotic stimuli. As
illustrated in Fig. 9A, withdrawal of NGF
from neuronally differentiated PC12 cells results in both an increase
in DLK protein levels and an enhanced signal of the most slowly
migrating form relative to that in control cells. The increases in
levels were apparent within 4 h of NGF deprivation, and the shift
to the most slowly migrating form was progressive over time up to
12 h of withdrawal. An increased level and upward mobility shift
of DLK protein was also observed in extracts of neuronal PC12 cells
after 4 h of UV treatment at a dose that induces apoptosis (Fig.
9B). These times are consistent with those previously reported for
elevations of JNK activity evoked by NGF deprivation (42,
69) and UV exposure (42, 53). The decreased
electrophoretic mobility of DLK associated with apoptotic stimuli
appeared to be due to enhanced phosphorylation in that it was abolished
by treatment of cell extracts with phosphatase (Fig. 9C). There is evidence that MLK3 is activated by phosphorylation (24),
and it therefore seems likely that the increases in levels and
phosphorylation of endogenous DLK induced by apoptotic stimuli reflect
its activation.
|
CEP-1347 protects neuronal PC12 cells from death evoked by MLKs and
upstream members of the JNK pathway.
CEP-1347 is an
indolocarbazole that effectively protects neurons and neuronal PC12
cells from a variety of apoptotic stimuli, including trophic factor
deprivation (42, 43, 54, 58). Mechanistic studies reveal
that CEP-1347 selectively blocks activation of the JNK pathway in
living cells and that in in vitro assays it inhibits the kinase
activity of MLK family members but not of a variety of other kinases
(42a). These CEP-1347 activities all occur in a similar
concentration range (50 to 200 nM). Such findings suggest that in
neuronal cells, in which MLKs are activated in response to apoptotic
stimuli, CEP-1347 provides protection from death by blocking MLK
activity and, consequently, activation of JNKs. We reasoned that if
this is the case, then CEP-1347 should protect neuronal cells from
death evoked by MLKs and upstream components of the JNK pathway but not
from death evoked by downstream pathway members. Neuronally
differentiated PC12 cells were pretreated with 200 nM CEP-1347 for
2 h and then transfected with MLK family members or with Rac1 V12
or Cdc42 V12. In all cases, the compound provided a significant
protection from death comparable to that achieved with BAF (Fig.
10). In contrast, when similar
experiments were carried out with the constitutively active form of
ASK1 (
N ASK1) and MKK4, there was no protection from death (Fig.
10).
|
Myr-AKT protects neuronal cells from death evoked by MLKs.
AKT
is an important component of the signaling pathways by which trophic
factors such as NGF protect neuronal cells from death (13,
66; reviewed in reference 18). Presumably, AKT acts in part by suppressing activation of the MLKs or other components of
the JNK pathway when NGF is present. To determine whether AKT might act
downstream of the MLKs, we cotransfected MLK family members together
with myristylated AKT (myr-AKT). Myr-AKT appears to be constitutively
activated when expressed in cells (19). The data depicted
in Fig. 11 show that myr-AKT
effectively suppressed death caused by overexpression of MLK, family
members. Cotransfection with wild-type AKT also suppressed death (data
not shown).
|
The role of ASK1 in the JNK apoptotic pathway.
ASK1 is
identified as an MKK kinase that can activate the JNK and p38 signaling
cascades (29). It was recently reported that
overexpression of
N ASK1 evokes death of neuronal PC12 cells and
sympathetic neurons and that a dominant-negative ASK1 partially protects such cells from death induced by NGF withdrawal
(32). We confirmed that
N ASK1 evokes death when
transfected into neuronal PC12 cells; however, the extent of death was
considerably less than that achieved with comparable amounts of cDNA
encoding MLKs (Fig. 10). Moreover, in contrast to its protective
effects against death evoked by activated Rac1 and Cdc42, MLKs, or NGF
withdrawal, CEP-1347 had little, if any, effect on the extent of death
promoted by
N ASK1 (Fig. 10). This finding indicates that ASK1 is
neither a target of CEP-1347 nor upstream of the MLKs.
N ASK1. As shown in Fig.
12, death caused by
N ASK1 overexpression was partially suppressed by dominant-negative MLK3 and
dominant-negative DLK. In the converse experiment, a kinase-inactive dominant-negative ASK1 construct also partially blocked death evoked by
MLK3 and DLK; however, it was not as effective in this regard as
dominant-negative MLK family members (Fig. 7a). In contrast, dominant-negative ASK1 was as effective as dominant-negative MLK3 and
dominant-negative DLK in suppressing death evoked by activated Rac1 and
Cdc42 (Fig. 7b).
|
| |
DISCUSSION |
|---|
|
|
|---|
Although several elements in the apoptotic signaling pathway that lead to JNK and c-Jun activation have been defined, the molecules that couple Rac1 and Cdc42 to activation of MKK4 and MKK7 in this pathway are less well understood. In this light, the drug CEP-1347 provided both a clue and a challenge. That is, since CEP-1347 blocks JNK activation (42) and appears to inhibit neither JNKs, MKKs, Rac1, nor Cdc42 directly (42a), there is another implied constituent that must be in the pathway and that is sensitive to the drug. The data provided here implicate MLK family members in this role.
Multiple forms of evidence indicate a role for the MLK family in the
neuronal apoptotic JNK/c-Jun pathway. First, transcripts for all
members of the MLK family are expressed in both naive and neuronally
differentiated PC12 cells and in sympathetic neurons. Moreover, at
least two members of the family (MLK3 and DLK) were found here to be
present at the protein level in PC12 cells. Multiple members of the MLK
family are also present in brain (12, 44, 57) (data not
shown). Second, overexpression of different members of the MLK family,
including MLK1, MLK2, MLK3, and DLK, induced significant cell death in
both neuronally differentiated and naive PC12 cells. In addition, the
two family members tested (DLK and MLK3) were also potent inducers of
apoptosis in cultured sympathetic neurons. This process was mediated by
activation of the JNK pathway, as indicated by its blockade by
coexpression of dominant-negative MKK4, dominant-negative MKK7, or
dominant-negative c-Jun. These observations are consistent with past
findings in nonneuronal cells demonstrating that MLK2, MLK3, and DLK
activate the JNK pathway though the activation of MKK7 and/or SEK1
(MKK4) and that expression of inactive SEK1 inhibits basal and
MLK3-activated JNK activity (4, 9, 25, 46, 56, 62, 63,
65). Third, dominant-negative forms of MLK family members
effectively protected neuronally differentiated PC12 cells and
sympathetic neurons from apoptosis induced by NGF deprivation. Fourth,
apoptotic stimuli led to both elevated levels and apparent activation
of endogenous DLK in neuronal PC12 cells. Lastly, CEP-1347, which protects sympathetic neurons and neuronally differentiated PC12 cells
from death evoked by NGF deprivation as well as a number of other
insults (42), also protected the cells from death elicited by overexpression of MLK family members. In contrast, the compound did
not protect against death caused by overexpression of MKK4 or
N
ASK1. This is consistent with recent findings identifying MLK family
members as specific targets of CEP-1347 (42a).
Our use of various JNK/c-Jun pathway constructs as well as of CEP-1347
permitted us to verify the order of the constituents of this pathway.
Rac1 and Cdc42 have been implicated as acting upstream of MKK4 and -7, JNKs, and c-Jun (1, 2, 8, 17, 27, 32, 47, 51, 62, 65).
Consistent with prior studies, our observations that dominant-negative
MLKs and CEP-1347 suppress death evoked by constitutively activated
forms of Rac1 and Cdc42 also place these GTPases upstream of the MLKs.
Furthermore, as anticipated, blockade of MLK-induced death by
dominant-negative MKK4 and -7 as well as by dominant-negative c-Jun
positions MLKs upstream of MKK4 and/or MKK7. A scheme summarizing this
pathway is shown in Fig. 13.
|
Cytoplasmic cytochrome c is known to cause neuronal death (11, 36, 49). It was recently reported that JNK null cells exhibit a defect in the mitochondrial death signaling mechanism, including the failure to release cytochrome c in response to apoptotic stimuli (64). This indicated that JNK activity is upstream of mitochondrial events in the death pathway. Our observation that MLK3 or DLK overexpression leads to loss of cytochrome c staining is consistent with this interpretation. The finding that cell death induced by overexpression of MLK family members can be prevented by general caspase inhibitors further suggests that MLKs act upstream of caspase activation.
JNK/c-Jun pathway activation has been found to elevate transcription of FAS ligand in some systems, and this has been suggested to contribute, in turn, to apoptotic death (40). We observed in neuronal PC12 cells that a dominant-negative form of FADD, which should interfere with FAS signaling, provided only a very limited protection from death elicited by MLK3 or DLK overexpression (Z. Xu, unpublished results). This suggests that regulated pathways other than those involving FAS and FADD are likely to play more major roles in death evoked by MLK or JNK activation. Alternatively, it is possible that FAS ligand may not depend completely on FADD to kill cells in our system.
What are the possible mechanisms by which MLK family members might be activated and by which they, in turn, phosphorylate their targets? In addition, what does the capacity, observed here, of various MLK dominant-negative forms to block death caused by other MLK family members tell us about these mechanisms? Overexpressed MLK3 and DLK can form homodimers through leucine zipper interactions, leading to autophosphorylation and activation, and such dimerization is a prerequisite for subsequent activation of JNKs (41, 44, 50). Vacratsis and Gallo (65) recently reported that constitutively activated Cdc42 fully activates a monomeric MLK3 leucine zipper mutant in terms of both autophosphorylation and histone phosphorylation activity and induces the same in vivo phosphorylation pattern as that of wild-type MLK3. However, this catalytically active monomeric MLK3 mutant is unable to stimulate JNK activation because it fails to phosphorylate one of the two activating phosphorylation sites, Thr258, of MKK4. These studies indicate that zipper-mediated MLK3 oligomerization is not required for MLK3 activation by Cdc42 but instead is critical for proper interaction and phosphorylation of a downstream target(s). This further suggests that one mechanism by which MLK and DLK dominant-negative forms act is by interfering with homodimerization required for substrate interaction.
In addition to blocking death caused by overexpression of their own wild-type counterparts, dominant-negative MLK3 and dominant-negative DLK also suppressed death evoked by other family members. One potential explanation is that various family members act in a cascade. For instance, on the basis that dominant-negative DLK suppresses MLK3-induced JNK1 activation, it was suggested that DLK functions downstream of MLK3 (60). However, in apparent disagreement with this possibility, we observed that dominant-negative MLK3 also effectively suppresses death evoked by DLK. A second model is that MLK3 and DLK form heterodimers whose function can be blocked by dominant-negative forms of either partner. Consistent with this, the two proteins can be coimmunoprecipitated (60). However, Nihalani et al. (50) recently provided evidence that MLK3 and DLK do not form heterodimers.
A third model, which is also consistent with coimmunoprecipitation, is that the MLK3 and DLK compete for binding to a common intermediary protein. For instance, it is possible that MLK3 and DLK (and their dominant-negative forms) compete for interaction with upstream activators such as Cdc42 and Rac1 and/or with the downstream kinases MKK4 and MKK7. For example, there is evidence that MLK2 and MLK3 associate with the activated (GTP-bound) forms of Rac1 and Cdc42 (48). Moreover, coexpression of activated Cdc42 with MLK3 leads to a substantial increase in MLK3 dimerization as well as altered MLK3 serine/threonine phosphorylation (4, 41). However, unlike the case of the PAK family of protein kinases, the activation of MLK3 by Cdc42 cannot be recapitulated in an in vitro system using purified, recombinant proteins (4). Such studies thus suggest that an additional component is required for MLK3 activation by Cdc42. Good candidates for this role would be scaffold proteins, such as JIP1 or POSH. The multidomain protein POSH binds to the constitutively active form of Rac1, which is known to regulate the activity of MLKs, while JIP1 binds to MLKs and additional components of the JNK pathway and appears to be capable of activating MLKs (50, 61, 67). Thus, it is attractive to consider the possibility that dominant-negative MLKs may act, at least in part, by competing for binding to a common scaffold protein that is required for activation of the JNK death pathway.
One question that is not currently resolved by our experiments is whether all or only a subset of MLK family members participate in the JNK apoptotic pathway. All appear to be expressed in the neuronal cell systems studied here, and all tested members of the family elicited death upon overexpression. This would suggest that multiple family members may indeed contribute to JNK activation and thereby to the death process.
Another kinase that has been raised as a potential upstream component
of the JNK apoptotic pathway in neurons is ASK1. Overexpression of
N
ASK1 evokes death of neuronal PC12 cells and sympathetic neurons,
apparently by activation of the JNK/c-Jun pathway, and dominant-negative ASK1 partially protects such cells from death caused
by NGF withdrawal (32). We observed that death stimulated by active ASK1, in contrast to death evoked by NGF deprivation and
other apoptotic stimuli, was not blocked by CEP-1347 and that dominant-negative ASK1 partially suppressed death caused by MLK3 and
DLK overexpression. Two main interpretations of these findings are
currently possible. One is that ASK1 lies downstream of MLKs in the JNK
pathway. However, our observation that dominant-negative MLK3 and
dominant-negative DLK reciprocally inhibit death evoked by
constitutively active ASK1 is inconsistent with this possibility. The
other interpretation is that ASK1 is not a major player in the JNK
death pathway activated by NGF withdrawal and that the protective
effects of dominant-negative ASK1 overexpression reflect nonspecific
competition with MLKs for interaction with Rac1, Cdc42, scaffold
proteins, or downstream targets.
We noted that death promoted by MLK family members and other elements
of the JNK pathway was suppressed by coexpression of a constitutively
active form of AKT (Fig. 11 and data not shown). AKT plays an important
role in mediating antiapoptotic activities of growth factors and
appears to do so in part by phosphorylating and affecting the
activities of a number of proapoptotic proteins, including caspase 9, BAD, I
B kinase, GSK3
, and FKHR (16; reviewed in
references 33 to 35). Although AKT was recently reported to inhibit the Rac1 signal transduction pathway (37), an
additional mechanism must be invoked in the present studies, since it
also provided protection from elements that are downstream of Rac1 in
the JNK death pathway. This indicates that AKT must suppress the
JNK-dependent death mechanism not only upstream or at the level of Rac1
activation but also at some point downstream of MLKs (which appear to
lack consensus sites for AKT phosphorylation). Although the identity of
the downstream AKT-sensitive element(s) is unknown, it is of interest
that many known substrates seem unlikely. Rat (the species used in our
studies) caspase 9 lacks the consensus site for phosphorylation by AKT,
and there is no current evidence that BAD is involved in death evoked
by NGF deprivation. Also, GSK3
and FKHR do not appear to be likely
downstream targets of the JNK pathway. This raises the possibility that
downstream of the JNK pathway there lies an additional novel AKT
substrate that regulates survival and death.
| |
ACKNOWLEDGMENTS |
|---|
We thank Michael J. Birrer, Thomas Franke, J. Silvio Gutkind, Alan Hall, Larry Holzman, Hidenori Ichijo, and Richard Spritz for plasmid constructs; James M. Angelastro, David X. Liu, and Jaya Padmanabhan (Columbia University) for helpful advice; Sheryl L. Meyer, Steve Trusko, and Chrysanthe Spais (Cephalon Inc.) for providing molecular reagents; and Claudine Bitel (Columbia University) for technical aid.
This work was supported in part by grants from the NIH-NINDS and Blanchette Rockefeller Foundation (L.A.G.).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Pathology, Columbia University, 630 W. 168th St., New York, NY 10032. Phone: (212) 305-6369. Fax: (212) 305-5498. E-mail: lag3{at}columbia.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bagrodia, S.,
B. Derijard,
R. J. Davis, and R. A. Cerione.
1995.
Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation.
J. Biol. Chem.
270:27995-27998 |
| 2. |
Bazenet, C. E.,
M. A. Mota, and L. L. Rubin.
1998.
The small GTP-binding protein Cdc42 is required for nerve growth factor withdrawal-induced neuronal death.
Proc. Natl. Acad. Sci. USA
95:3984-3989 |
| 3. |
Bhat, R. V.,
R. DiRocco,
V. R. Marcy,
D. G. Flood,
Y. Zhu,
P. Dobrzanski,
R. Siman,
R. Scott,
P. C. Contreras, and M. Miller.
1996.
Increased expression of IL-1 beta converting enzyme in hippocampus after ischemia: selective localization in microglia.
J. Neurosci.
16:4146-4154 |
| 4. |
Bock, B. C.,
P. O. Vacratsis,
E. Qamirani, and K. A. Gallo.
2000.
Cdc42-induced activation of the mixed-lineage kinase SPRK in vivo. Requirement of the Cdc42/Rac interactive binding motif and changes in phosphorylation.
J. Biol. Chem.
275:14231-14241 |
| 5. |
Burbelo, P. D.,
D. Drechsel, and A. Hall.
1995.
A conserved binding motif defines numerous candidate target proteins for both Cdc42 and Rac GTPases.
J. Biol. Chem.
270:29071-29074 |
| 6. | Cai, J., J. Yang, and D. P. Jones. 1998. Mitochondrial control of apoptosis: the role of cytochrome c. Biochim. Biophys. Acta 1366:139-149[Medline]. |
| 7. | Chuang, T. H., K. M. Hahn, J. D. Lee, D. E. Danley, and G. M. Bokoch. 1997. The small GTPase Cdc42 initiates an apoptotic signaling pathway in Jurkat T lymphocytes. Mol. Biol. Cell 8:1687-1698[Abstract]. |
| 8. | Coso, O. A., M. Chiariello, J. C. Yu, H. Teramoto, P. Crespo, N. Xu, T. Miki, and J. S. Gutkind. 1995. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 81:1137-1146[CrossRef][Medline]. |
| 9. | Cuenda, A., and D. S. Dorow. 1998. Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1. Biochem. J. 333:11-15. |
| 10. | Desagher, S., and J. C. Martinou. 2000. Mitochondria as the central control point of apoptosis. Trends Cell Biol. 10:369-377[CrossRef][Medline]. |
| 11. | Deshmukh, M., and E. M. Johnson, Jr. 1998. Evidence of a novel event during neuronal death: development of competence-to-die in response to cytoplasmic cytochrome c. Neuron 21:695-705[CrossRef][Medline]. |
| 12. | Dorow, D. S., L. Devereux, G. F. Tu, G. Price, J. K. Nicholl, G. R. Sutherland, and R. J. Simpson. 1995. Complete nucleotide sequence, expression, and chromosomal localisation of human mixed-lineage kinase 2. Eur. J. Biochem. 234:492-500[Medline]. |
| 13. |
Dudek, H.,
S. R. Datta,
T. F. Franke,
M. J. Birnbaum,
R. Yao,
G. M. Cooper,
R. A. Segal,
D. R. Kaplan, and M. E. Greenberg.
1997.
Regulation of neuronal survival by the serine-threonine protein kinase Akt.
Science
275:661-665 |
| 14. |
Eilers, A.,
J. Whitfield,
C. Babij,
L. L. Rubin, and J. Ham.
1998.
Role of the Jun kinase pathway in the regulation of c-Jun expression and apoptosis in sympathetic neurons.
J. Neurosci.
18:1713-1724 |
| 15. |
Estus, S.,
W. J. Zaks,
R. S. Freeman,
M. Gruda,
R. Bravo, and E. M. Johnson, Jr.
1994.
Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis.
J. Cell Biol.
127:1717-1727 |
| 16. |
Eves, E. M.,
W. Xiong,
A. Bellacosa,
S. G. Kennedy,
P. N. Tsichlis,
M. R. Rosner, and N. Hay.
1998.
Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line.
Mol. Cell. Biol.
18:2143-2152 |
| 17. |
Foltz, I. N.,
R. E. Gerl,
J. S. Wieler,
M. Luckach,
R. A. Salmon, and J. W. Schrader.
1998.
Human mitogen-activated protein kinase kinase 7 (MKK7) is a highly conserved c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) activated by environmental stresses and physiological stimuli.
J. Biol. Chem.
273:9344-9351 |
| 18. | Franke, T. F., D. R. Kaplan, and L. C. Cantley. 1997. P13K: downstream AKTion blocks apoptosis. Cell 88:435-437[CrossRef][Medline]. |
| 19. | Franke, T. F., S. I. Yang, T. O. Chan, K. Datta, A. Kazlauskas, D. K. Morrison, D. R. Kaplan, and P. N. Tsichlis. 1995. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727-736[CrossRef][Medline]. |
| 20. | Garrington, T. P., and G. L. Johnson. 1999. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. 11:211-218[CrossRef][Medline]. |
| 21. |
Greene, L. A., and A. S. Tischler.
1976.
Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.
Proc. Natl. Acad. Sci. USA
73:2424-2428 |
| 22. | Ham, J., C. Babij, J. Whitfield, C. M. Pfarr, D. Lallemand, M. Yaniv, and L. L. Rubin. 1995. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14:927-939[CrossRef][Medline]. |
| 23. | Ham, J., A. Eilers, J. Whitfield, S. J. Neame, and B. Shah. 2000. c-Jun and the transcriptional control of neuronal apoptosis. Biochem. Pharmacol. 60:1015-1021[CrossRef][Medline]. |
| 24. |
Hehner, S. P.,
T. G. Hofmann,
A. Ushmorov,
O. Dienz,
I. Wing-Lan Leung,
N. Lassam,
C. Scheidereit,
W. Droge, and M. L. Schmitz.
2000.
Mixed-lineage kinase 3 delivers CD3/CD28-derived signals into the I B kinase complex.
Mol. Cell. Biol.
20:2556-2568 |
| 25. |
Hirai, S.,
M. Katoh,
M. Terada,
J. M. Kyriakis,
L. I. Zon,
A. Rana,
J. Avruch, and S. Ohno.
1997.
MST/MLK2, a member of the mixed lineage kinase family, directly phosphorylates and activates SEK1, an activator of c-Jun N-terminal kinase/stress-activated protein kinase.
J. Biol. Chem.
272:15167-15173 |
| 26. | Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59[CrossRef][Medline]. |
| 27. |
Holland, P. M.,
M. Suzanne,
J. S. Campbell,
S. Noselli, and J. A. Cooper.
1997.
MKK7 is a stress-activated mitogen-activated protein kinase kinase functionally related to hemipterous.
J. Biol. Chem.
272:24994-24998 |
| 28. |
Holzman, L. B.,
S. E. Merritt, and G. Fan.
1994.
Identification, molecular cloning, and characterization of dual leucine zipper bearing kinase. A novel serine/threonine protein kinase that defines a second subfamily of mixed lineage kinases.
J. Biol. Chem.
269:30808-30817 |
| 29. |
Ichijo, H.,
E. Nishida,
K. Irie,
P. ten Dijke,
M. Saitoh,
T. Moriguchi,
M. Takagi,
K. Matsumoto,
K. Miyazono, and Y. Gotoh.
1997.
Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways.
Science
275:90-94 |
| 30. | Ing, Y. L., I. W. Leung, H. H. Heng, L. C. Tsui, and N. J. Lassam. 1994. MLK-3: identification of a widely-expressed protein kinase bearing an SH3 domain and a leucine zipper-basic region domain. Oncogene 9:1745-1750[Medline]. |
| 31. |
Ip, Y. T., and R. J. Davis.
1998.
Signal transduction by the c-Jun N-terminal kinase (JNK) from inflammation to development.
Curr. Opin. Cell Biol.
10:205-219[CrossRef][Medline].
|
| 32. |
Kanamoto, T.,
M. Mota,
K. Takeda,
L. L. Rubin,
K. Miyazono,
H. Ichijo, and C. E. Bazenet.
2000.
Role of apoptosis signal-regulating kinase in regulation of the c-Jun N-terminal kinase pathway and apoptosis in sympathetic neurons.
Mol. Cell. Biol.
20:196-204 |
| 33. | Kandel, E. S., and N. Hay. 1999. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 253:210-229[CrossRef][Medline]. |
| 34. | Kaplan, D. R., and F. D. Miller. 2000. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10:381-391[CrossRef][Medline]. |
| 35. | Kops, G. J., and B. M. Burgering. 1999. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J. Mol. Med. 77:656-665[CrossRef][Medline]. |
| 36. |
Krajewski, S.,
M. Krajewska,
L. M. Ellerby,
K. Welsh,
Z. Xie,
Q. L. Deveraux,
G. S. Salvesen,
D. E. Bredesen,
R. E. Rosenthal,
G. Fiskum, and J. C. Reed.
1999.
Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia.
Proc. Natl. Acad. Sci. USA
96:5752-5757 |
| 37. |
Kwon, T.,
D. Y. Kwon,
J. Chun,
J. H. Kim, and S. S. Kang.
2000.
Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1.
J. Biol. Chem.
275:423-428 |
| 38. |
Kyriakis, J. M., and J. Avruch.
1996.
Sounding the alarm: protein kinase cascades activated by stress and inflammation.
J. Biol. Chem.
271:24313-24316 |
| 39. | Lee, V. M., M. L. Shelanski, and L. A. Greene. 1980. Characterization of antisera raised against cultured rat sympathetic neurons. Neuroscience 5:2239-2245 |